A Guide To Drug-Drug Interactions In Podiatry

Start Page:

Understanding How Drugs Affect Enzymes

The major group of enzymes in the liver responsible for metabolizing drugs can be isolated in a sub-cellular fraction termed the “microsomes.” Cytochrome P450 is a “superfamily” of enzymes that are the terminal oxidases of this oxidation system. “Cytochrome” means colored cells. These enzymes contain iron and give the liver its red color. The name “P450” comes from the observation that the enzyme absorbs a very characteristic wavelength (450 nm) of ultraviolet light when it is exposed to carbon monoxide.

These enzymes are named according to families that are defined by the similarity of their amino acid sequence. These P450 iso-enzymes are denoted with the following numbers and letters: CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4.10-12 More than 50 percent of currently used medications that are metabolized undergo CYP3A4 metabolism.

The CYP3A subfamily is of particular interest because it is responsible for the metabolism of a large number of clinically important drugs in humans.11 The CYP3A4 isozyme accounts for over 25 percent of hepatic CYP450 content and is responsible for over half of all CYP450-mediated drug metabolisms. About 14 percent of the adult liver contains a substantial proportion of CYP3A5. However, it is proportionally more important in intestinal tissue and is the primary CYP3A enzyme in the kidney.11,12

A drug that is metabolized by a particular isoenzyme is a substrate for that enzyme. A drug can be a substrate for several different isoenzymes or an active metabolite can be a substrate for a different isoenzyme to the parent drug. These pharmacokinetic drug interactions affecting metabolism are often clinically significant and can involve induction (increased metabolism) or inhibition (reduced metabolism) of enzymes. Competition between two drugs for cytochrome P450 isozymes will occur. This competition may result in one drug interfering with the metabolism of another drug.

Medications metabolized by CYP3A4 or CYP2C9 are particularly susceptible to enzyme induction. Drugs known as “enzyme inducers” are capable of increasing the activity of drug metabolizing enzymes, resulting in a decrease in the effect of certain other drugs. For therapeutic agents that undergo extensive first-pass metabolism by CYP3A in the gut wall and liver, the reduction in serum concentrations of object drugs by enzyme inducers (precipitant drugs) can be profound. Enzyme inducers can increase the formation of toxic metabolites and increase the risk of hepatotoxicity as well as damage to other organs.

Author(s): 
Robert G. Smith, DPM, MSc, RPh, CPed

16. Brüggemann RJM, Alffenaar JC, Blijlevens NM et al. Clinical relevance of the pharmaokinetic interactions of azole antifungal drugs with other coadministered agents: Reviews of anti-infective agents. Clin Infect Dis. 2009; 48(10):1441-1458.

17. Yu DT. Peterson JF, Seger DL, et al. Frequency of potential azole drug-drug interactions and consequences of potential fluconazole drug interactions. Pharmacoepidemiol Drug Saf. 2005; 14(11):755-767.

18. Lazar JD, Wilner KD. Drug interactions with fluconazole. Rev Infect Dis. 1990; 12(3):S327-S333.

19. Angirasa AK, Koch AZ. P-glycoprotein as the mediator of itraconazole-digoxin interaction. J Am Podiatr Med Assoc. 2002; 92(8):471-472.

20. Hughes J, Crowe A. Inhibition of P-glycoprotein-mediated efflux of digoxin and its metabolites by macrolide antibiotics. J Pharmacol Sci. 2010; 113(4):315-324.

21. Schelleman H, Bilker WB, Brensinger CM et al. Warfarin with fluroquinolones, sulfonamides, or azole antifungals: interactions and the risk of hospitalization for gastrointestinal bleeding. Clin Pharmacol Ther. 2008; 84(5):581-588.

22. Johnson AG, Seidemann P, Day RO. Adverse drug interactions with nonsteroidal anti-inflammatory drugs (NSAIDs). Recognition, management and avoidance. Drug Saf. 1993; 8(2):99-127.

23. Johnson AG, Seidemann P, Day RO. NSAID-related adverse drug interactions with clinical relevance. An update. Int J Clin Pharmacol Ther. 1994; 32(10):509-532.

24. Guo Q, Sun S, Li Y et al. In vitro interactions between azoles and amiodarone against clinical Candida albicans. Int J Antimicrob Agents. 2008; 31(1):88-90.

25. Ohyama K, Nakajima M, Suzuki M, et al. Inhibitory effects of amiodarone and its N-deethylate metabolite on human cytochrome P450 activities: Prediction of in vivo drug interactions. Br J Clin Pharmacol. 2000; 49(3):244-253.

26. MacDonald L, Foster BC, Akhtar H. Food and therapeutic product interactions- a therapeutic perspective. J Pharm Pharmaceut Sci. 2009; 12(3):367-377.

27. Gonzalez Canga A, Fernandez Martinez N, Sahagun Prieto AM, et al. Dietary fiber and its interaction with drugs. Nutr Hosp. 2010; 25(5):535-539.

28. Shimomura S, Wanwimolruk S, Chen JJ. Drug Interactions with grapefruit juice: an evidence-base overview. Pharmacy Times. Available at https://secure.pharmacytimes.com/lessons/200303-02.asp .

29. Smith RG. An appraisal of potential drug interactions in cigarette smokers and alcohol drinkers. J Am Podiatr Med Assoc. 2009; 99(1):81-88.

30. Smith RG. Illicit drug abuse implications for the podiatric physician. Podiatry Management. 2009; 28(3):171-184.

31. Zhou SF, Xue CC, Yu XQ et al. Clinically important drug interactions potentially involving mechanism-based inhibitition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit. 2007; 29(6):687-710.

32. Ament PW Bertolino JG, Liszewski JL. Clinically significant drug interactions. Am Fam Physician. 2000; 61(6):745-1754.

33. Chandragiri SS, Pasol E, Gallagher RM. Lithium, Ace inhibitors, NSAIDs, and Verapamil: a possible fatal combination. Psychosomatics. 1998; 39(3):281-282.

image description image description


Post new comment

  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

More information about formatting options

Image CAPTCHA
Enter the characters shown in the image.